- Home
- UMAC vs MREO Comparison
UMAC vs MREO Comparison
Compare UMAC & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$2.31
Company Overview
Basic Information| Metric | UMAC | MREO |
|---|---|---|
| Founded | 2019 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.5M | 324.6M |
| IPO Year | 2024 | N/A |
Fundamental Metrics
Financial Performance| Metric | UMAC | MREO |
|---|---|---|
| Price | $12.21 | $2.31 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $20.00 | $7.20 |
| AVG Volume (30 Days) | 2.1M | ★ 2.6M |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,304,873.00 | $500,000.00 |
| Revenue This Year | $84.19 | N/A |
| Revenue Next Year | $166.17 | $163.84 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 133.20 | N/A |
| 52 Week Low | $4.45 | $1.47 |
| 52 Week High | $21.65 | $3.88 |
Technical Indicators
Market Signals| Indicator | UMAC | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 59.61 | 62.66 |
| Support Level | $8.66 | $1.89 |
| Resistance Level | $13.35 | $2.35 |
| Average True Range (ATR) | 0.99 | 0.15 |
| MACD | 0.42 | 0.02 |
| Stochastic Oscillator | 78.04 | 87.63 |
Price Performance
Historical Comparison UMAC
MREO
About UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in serving the American drone industry by building and selling drone components.
About MREO Mereo BioPharma Group plc
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).